BioinvestGPT ApS · Research use only

BVCT solutions

19 case studies and newsletters from BioinvestGPT, each featuring a unique BVCT capability, from atom-level clinical benefit prediction, patient-data-free calls made before the first patient enrols, first-in-class mechanism calls that look past the biomarker, any-phase calls spanning Phase 1/2 and Phase 3, pipeline-level GO/NO-GO calls, portfolio-wide NO-GO calls shared before the readouts, clinical benefit prediction from mRNA sequence, Phase 3 outcome calls made well before the readout, PFS/OS discordance calls, overall-survival calls in HER2-positive cancers, sealed calls on the year’s most-watched readouts, variant-level clinical derisking before wet-lab spend, verification of AI co-scientist hypotheses, patient-data-free AI with no jailbreak surface, in vivo CAR-T design simulation, ADC design and biomarker discovery, clinical prediction from the genome alone, mathematics-based hazard-ratio prediction, to a self-service GO/NO-GO web app. Each cited prediction links to its trial page, with the prediction date, the recorded calls and the readout classification.